Journal Article

A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates

Czoty, Paul W., Husbands, Stephen M., Ding, Huiping, Cami-Kobeci, Gerta, Ko, Mei-Chuan, Nader, Michael A., Kiguchi, Norikazu, Sukhtankar, Devki D.

2016

Overview

Despite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys using clinically used MOP receptor agonists for side-by-side comparisons in various well-honed behavioral and physiological assays. Systemic BU08028 (0.001–0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists. More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration. Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ∼10-to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices. After repeated administration, the monkeys developed acute physical dependence on morphine, as manifested by precipitated withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure. In contrast, monkeys did not show physical dependence on BU08028. These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abusefree opioid analgesics.

• Publisher: National Academy of Sciences
• Subject: Analgesics / Analgesics, Opioid - administration & dosage / Analgesics, Opioid - adverse effects / Analgesics, Opioid - agonists / Analgesics, Opioid - antagonists & inhibitors / Animals / Biological Sciences / Blood pressure / Buprenorphine - administration & dosage / Buprenorphine - adverse effects / Buprenorphine - analogs & derivatives / Buprenorphine - chemistry / Buprenorphine - metabolism / Cocaine / Cocaine - toxicity / Drug abuse / Drug-Related Side Effects and Adverse Reactions - pathology / Heart rate / Humans / Liability / Ligands / Monkeys & apes / Narcotics / Opioid Peptides - agonists / Opioid Peptides - antagonists & inhibitors / Pain - drug therapy / Pain - pathology / Peptides / Pharmacology / PNAS Plus / Primates / Receptors, Opioid, mu - agonists / Receptors, Opioid, mu - antagonists & inhibitors / Respiratory Insufficiency - chemically induced / Respiratory Insufficiency - pathology / Telemetry